Enhertu Phase III results to redefine how metastatic breast cancer is classifed
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Sputnik Light can become a major booster for those vaccinated with inactivated Chinese Covid-19 vaccines globally after China has officially recommended mix & match approach with adenoviral vector-based vaccines as boosters
According to the Indian Journal of Medical Research in 2018, the estimated prevalence of pre-diabetes in India is 14%, which means that one out of six Indians is pre-diabetic
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
The grants are expected to be received over the next three years, commencing March 2022
The companies plan to use the proceeds to retire debt and expand operations
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Subscribe To Our Newsletter & Stay Updated